CNS Pharma rises on clearance for brain cancer drug trial in Switzerland

CNS Pharmaceuticals

02/12/2021 14:39

** Cancer-focused drug developer  CNSP.O  rises 4.73% to
$1.11
    ** Says it got approval from Switzerland's ethics committee
for a key study testing its lead drug candidate, berubicin, for
the treatment of recurrent glioblastoma multiforme - one of the
most aggressive types of brain cancer  urn:newsml:reuters.com:*:nPnl8C1Na
    ** The company's global trial would involve 243 patients,
with the main goal being overall survival - which measures the
length of time for which patients diagnosed are alive 
    ** CNSP started dosing patients in the trial with berubicin
in September
    ** The drug has received "fast track" designation from the
U.S. FDA, enabling more frequent interactions with the agency
    ** Stock had fallen 40.5% this year, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))